Cargando…
Mucormycosis in COVID Diabetic Patients: A Horrifying Triad!
Infectious diseases with the coronavirus disease-2019 (COVID-19) can be linked to various microbial and fungal coinfections. Mucormycosis is an invasive opportunistic infection that enters as inhalation of fungal spores through the nose or paranasal sinuses in diabetic and immunocompromised patients...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Jaypee Brothers Medical Publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608646/ https://www.ncbi.nlm.nih.gov/pubmed/34866832 http://dx.doi.org/10.5005/jp-journals-10071-24025 |
_version_ | 1784602786632040448 |
---|---|
author | Panwar, Parshika Gupta, Anish Kumar, Amit Gupta, Bhavna Navriya, Shiv C |
author_facet | Panwar, Parshika Gupta, Anish Kumar, Amit Gupta, Bhavna Navriya, Shiv C |
author_sort | Panwar, Parshika |
collection | PubMed |
description | Infectious diseases with the coronavirus disease-2019 (COVID-19) can be linked to various microbial and fungal coinfections. Mucormycosis is an invasive opportunistic infection that enters as inhalation of fungal spores through the nose or paranasal sinuses in diabetic and immunocompromised patients. We present our experience of managing seven cases of recent COVID-19 infection with uncontrolled diabetes who developed rhino-orbital mucormycosis. All patients were diagnosed by clinical examination and imaging and managed by emergency surgical debridement and liposomal amphotericin-B. A lethal triad of impaired immunity due to COVID-19 infection, state of hyperglycemia, increased use of steroids, or rampant broad-spectrum antimicrobials works as fertile soil and may assist in the growth or alleviation of a fungal infection. Healthcare professionals must be aware of the potential of secondary invasive fungal infections in diabetic patients with moderate to severe category of COVID-19 infectious disease, especially on steroid therapy. HOW TO CITE THIS ARTICLE: Panwar P, Gupta A, Kumar A, Gupta B, Navriya SC. Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! Indian J Crit Care Med 2021;25(11):1314–1317. |
format | Online Article Text |
id | pubmed-8608646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Jaypee Brothers Medical Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-86086462021-12-02 Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! Panwar, Parshika Gupta, Anish Kumar, Amit Gupta, Bhavna Navriya, Shiv C Indian J Crit Care Med Case Series Infectious diseases with the coronavirus disease-2019 (COVID-19) can be linked to various microbial and fungal coinfections. Mucormycosis is an invasive opportunistic infection that enters as inhalation of fungal spores through the nose or paranasal sinuses in diabetic and immunocompromised patients. We present our experience of managing seven cases of recent COVID-19 infection with uncontrolled diabetes who developed rhino-orbital mucormycosis. All patients were diagnosed by clinical examination and imaging and managed by emergency surgical debridement and liposomal amphotericin-B. A lethal triad of impaired immunity due to COVID-19 infection, state of hyperglycemia, increased use of steroids, or rampant broad-spectrum antimicrobials works as fertile soil and may assist in the growth or alleviation of a fungal infection. Healthcare professionals must be aware of the potential of secondary invasive fungal infections in diabetic patients with moderate to severe category of COVID-19 infectious disease, especially on steroid therapy. HOW TO CITE THIS ARTICLE: Panwar P, Gupta A, Kumar A, Gupta B, Navriya SC. Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! Indian J Crit Care Med 2021;25(11):1314–1317. Jaypee Brothers Medical Publishers 2021-11 /pmc/articles/PMC8608646/ /pubmed/34866832 http://dx.doi.org/10.5005/jp-journals-10071-24025 Text en Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd. https://creativecommons.org/licenses/by-nc/4.0/© The Author(s). 2021 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Series Panwar, Parshika Gupta, Anish Kumar, Amit Gupta, Bhavna Navriya, Shiv C Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! |
title | Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! |
title_full | Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! |
title_fullStr | Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! |
title_full_unstemmed | Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! |
title_short | Mucormycosis in COVID Diabetic Patients: A Horrifying Triad! |
title_sort | mucormycosis in covid diabetic patients: a horrifying triad! |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608646/ https://www.ncbi.nlm.nih.gov/pubmed/34866832 http://dx.doi.org/10.5005/jp-journals-10071-24025 |
work_keys_str_mv | AT panwarparshika mucormycosisincoviddiabeticpatientsahorrifyingtriad AT guptaanish mucormycosisincoviddiabeticpatientsahorrifyingtriad AT kumaramit mucormycosisincoviddiabeticpatientsahorrifyingtriad AT guptabhavna mucormycosisincoviddiabeticpatientsahorrifyingtriad AT navriyashivc mucormycosisincoviddiabeticpatientsahorrifyingtriad |